Prostate Cancer Serum
Prostate Cancer Serum - IRB-consented human serum from donors with clinically confirmed prostate cancer, frozen within 24 hours. Useful for PSA and PSA-isoform assay work, androgen and hormonal analytes, inflammatory protein profiling, and bone turnover markers in metastatic disease. Grade group, stage, and treatment stratification available.
Human Prostate Cancer Serum for Oncology Biomarker Research
Our Prostate Cancer Serum is sourced from IRB-consented donors clinically diagnosed with prostate cancer. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for tumor biomarker, hormonal, and inflammatory studies. Available in standard and custom volumes. Research Use Only (RUO).
Tumor Biology and Why Serum
- Prostate adenocarcinoma is characteristically dependent on androgen receptor signaling, which is why androgen deprivation is the backbone of systemic therapy and why hormonal analytes are central to research design.
- Prostate-specific antigen (PSA) is the kallikrein-family protease encoded by KLK3; it is androgen-regulated, secreted, and the most established circulating marker in the disease, measurable in serum as total and free PSA.
- PSA-derived measures including free-to-total ratio and PSA isoforms such as [-2]proPSA are used in research to improve discrimination beyond total PSA alone, which lacks specificity for clinically significant disease.
- Disease heterogeneity is substantial: Gleason grade group and stage separate indolent from aggressive disease, and most lethal disease progresses to castration-resistant prostate cancer despite ongoing androgen suppression.
- Bone is the dominant site of metastasis, so bone turnover analytes and alkaline phosphatase are commonly studied in advanced-disease serum; neuroendocrine differentiation is associated with markers such as chromogranin A.
- Serum is acellular and is therefore the appropriate matrix for secreted protein, hormone, and cytokine immunoassays rather than any cell-based readout.
Donor Stratification Available
- Gleason grade group and stage at diagnosis
- Localized versus locally advanced versus metastatic disease
- Hormone-sensitive versus castration-resistant disease
- Treatment status: treatment-naive, on androgen deprivation therapy, on androgen receptor pathway inhibitor, on chemotherapy, or post-prostatectomy or radiotherapy
- Presence and site of metastasis, particularly bone
- PSA level at collection where documented, plus age and self-reported race/ethnicity
- Matched healthy controls available
Product Features
- Collected from clinically confirmed prostate cancer donors
- Processed and frozen within 24 hours of collection
- Research Use Only (RUO)
- Standard and custom aliquot volumes available
- IRB-approved protocols with documented electronic consent
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported medical history, medications, and comorbidities
- Gleason grade group, stage, and treatment history where available
- Additional prostate cancer-specific metadata on request
Applications
- PSA immunoassay development, calibration, and validation
- Free, total, and isoform PSA comparative studies
- Androgen and steroid hormone analyte research
- Serum cytokine and inflammatory protein profiling
- Bone turnover marker studies in metastatic disease
- Serum proteomics and metabolomics for biomarker discovery
- Therapeutic candidate screening and treatment-response research
- Disease-state matrix for diagnostic assay verification and lot qualification
Other Prostate Cancer Specimen Types
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Prostate Cancer Serum is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse all matrices and disease states, visit our human serum page.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.